Navigation Links
Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
Date:9/30/2013

SAN DIEGO, Sept. 30, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced mature patient progression free survival (PFS) and ongoing overall survival (OS) data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with gemcitabine for the treatment of patients with stage IV metastatic pancreatic cancer. In the trial, both PFS and OS data suggest a potential clinical benefit of using PEGPH20 with gemcitabine in patients with high levels of tumor associated hyaluronan (HA). These results are being presented at European Cancer Congress 2013 (ECCO-ESMO-ESTRO) in a poster session at 14:00 CEST (Hall 4, Abstract #2598). Early response rates from this trial were previously presented at the 2013 American Society of Clinical Oncology (ASCO) Annual meeting in June 2013.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The accumulation of HA, a protective matrix that surrounds many solid tumors, has been shown to be an indicator of poor patient prognosis and may accelerate disease progression. In this single arm study, all patients received PEGPH20 in combination with gemcitabine. The primary objective was to determine the recommended phase 2 dose. Exploratory analysis evaluated PFS and OS in a subset of patients with available biopsy samples and HA scores. In patients with high levels of tumor HA (n=6), PFS was 219 days compared to 108 days for patients with low levels of tumor HA (n=11), while OS in the high HA group was 529 days compared to 174 days for the low HA group. OS data is still not mature for the high HA group. With respect to the intent to treat population irrespective of HA status (n=24), PFS was 154 days and OS was 200 days.

"PEGPH20 has been shown in animal studies to deplete H
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
2. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
3. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
4. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
5. Halozyme Reports Second Quarter 2013 Financial Results
6. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
7. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
8. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
9. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
10. Halozyme Reports First Quarter 2013 Financial Results
11. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SAN DIEGO , July 29, 2014 Pfenex ... its previously announced initial public offering of 8,333,333 shares of ... $6.00 per share. All of the common stock was offered ... 30-day option to purchase up to 1,250,000 additional shares of ... of common stock are traded on the NYSE MKT under ...
(Date:7/29/2014)... 2014 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today reported net income for the quarter ... diluted share, and non-GAAP net income of $94.0 million, or ... a year earlier was $93.3 million, or $0.81 per diluted ... per diluted share.  Net sales for the ...
(Date:7/29/2014)... ALBANY, New York , July 29, 2014 /PRNewswire/ ... published by Transparency Market Research "Surgical Navigation Systems Market ... Systems) - Global Industry Analysis, Size, Share, Growth, Trends ... systems market was valued at USD 218.5 million in ... of 4.5% from 2014 to 2020, to reach an ...
Breaking Medicine Technology:Pfenex Announces Closing of Initial Public Offering 2Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4
... Pa., April 14 Consumers who,purchased raw milk ... after March 18 should discard it immediately due ... Dennis Wolff,said today., Raw milk is milk ... selling raw milk must be permitted and have ...
... cisplatin observed in ovarian carcinoma xenografts, DUBLIN, ... ), a pharmaceutical company dedicated to the discovery, ... and,hematological malignancies, today announced as part of a ... that S-110, its DNA,methyltransferase inhibitor, improves in vivo ...
Cached Medicine Technology:SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine 2SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine 3
(Date:7/30/2014)... 30, 2014 The San Diego personal injury ... are announcing that they are now offering free case reviews ... asbestos exposure. , “Symptoms of asbestos exposure can take ... toxin 30 plus years ago may just now be suffering ... Law Office of Melinda J. Helbock A.P.C. “We want people ...
(Date:7/30/2014)... Connecticut (PRWEB) July 30, 2014 Pain ... new magnetic sports bracelet for pain relief and improved ... strength carbonized titanium embedded in a silicone core that ... also has Germanium and is embedded with scalar energy ... bracelet. , “Pain Free Living has 12 years experience ...
(Date:7/30/2014)... Nuanced Media, a specialist in web design and digital ... Web Design Trends of 2014. The web design trends ... and the medical web design industry throughout the year. , ... grows. Therefore it is important for existing practices and new ... New trends are defined by advances in the medical industry ...
(Date:7/29/2014)... Cucamonga, CA (PRWEB) July 29, 2014 Paul ... Ways to Make More Money in 30 Days” E-book. The ... anyone can use to make extra cash. Examples include downloading ... utilizing unique free websites that help people monetize the assets ... and even unused items they can find in their garage. ...
(Date:7/29/2014)... 30, 2014 Saint Luke’s Medical ... awarded the Patient-Centered Medical Home 2011 Level 3 ... for Quality Assurance. Only one out of four ... Level 2, or Level 3 recognition. , Patients ... Medical Home report faster access to their doctors, ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Nuanced Media Releases "Medical Web Design Trends of 2014" Article 2Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2
... Cause of Death in Long-Term Survivors of Hereditary Retinoblastoma ... increased risk of death due to a second cancer, ... a very rare cancer of the eye that affects ... of retinoblastoma are at risk of subsequent malignancies but ...
... Hear Public Comments on Comparative Effectiveness Research ... 7 The Federal Coordinating Council for ... listening session on April 14, 2009, in ... comment regarding comparative effectiveness research and the ...
... to worse outcomes , , TUESDAY, April 7 (HealthDay News) ... more likely to die or need a second heart ... according to the results of a U.S. study. , ... who received their first heart transplant at Children,s Hospital ...
... but activity is safe and should be urged, expert says, ... of moderate exercise will not harm people with heart failure ... has found. , That admittedly tepid conclusion comes from a ... at 82 centers in the United States, Canada and France. ...
... Mayo Clinic researchers have discovered the mechanisms behind two ... that may ultimately allow investigators to benchmark progression of ... findings appear in the current online issue of ... by Edward Leof, Ph.D. , Mayo Clinic biochemist, ...
... of Global Breast Cancer Movement Continues Unprecedented Investment ... Committed to caring for those coping with ... of the disease, Susan G. Komen for the ... announced $60 million in research grants to U.S. ...
Cached Medicine News:Health News:Also in the April 7 JNCI 2Health News:Also in the April 7 JNCI 3Health News:Also in the April 7 JNCI 4Health News:Federal Coordinating Council on Comparative Effectiveness Research to Hold Public Listening Session in Washington, DC 2Health News:Heart Transplant Failures More Likely in Poor, Minority Kids 2Health News:Exercise Might Benefit Some With Heart Failure 2Health News:Exercise Might Benefit Some With Heart Failure 3Health News:Mayo researchers discover mechanism of cell type-specific signaling in tumor development 2Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 2Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 3Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 4Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 5
... continuous low-flow nebulizer performance. Patented auxiliary ... allows for optimal medication and Heliox ... OMNI~NEB takes on severe asthma, COPD ... critical care situations. Configure with a ...
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
... Mouthpiece 7FT O 2 Tubing Tee Adapter ... are designed to provide maximum aerosol quality and ... fast treatment time. Each of these high-efficiency nebulizers ... vent seal adapter for use with your ventilator ...
Nebulizer Custom Kit...
Medicine Products: